

SEQUANA MEDICAL NV

Public limited liability company

Registered office: Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium
VAT BE 0707.821.866 Register of Legal Entities Ghent, section Ghent

CORPORATE GOVERNANCE CHARTER

TABLE OF CONTENT

Section	Page
1. Introduction	3
2. General information	3
3. Board of Directors	4
4. Audit committee.....	13
5. Remuneration and nomination committee	16
6. Executive management	19
7. Shares and shareholders	21
8. Miscellaneous.....	24

1. INTRODUCTION

This Corporate Governance Charter (the "**Charter**") has been prepared by Sequana Medical NV (the "**Company**") in accordance with the Belgian Code on Corporate Governance of 2020 (the "**Belgian Code on Corporate Governance**"). This Charter describes the main aspects of the corporate governance of the Company, including its governance structure, the terms of reference of the board of directors and its committees, and other important topics. The Charter must be read together with the Company's articles of association. The Charter and the articles of association are available on the Company's website (www.sequanamedical.com) and can be obtained free of charge at the Company's registered office.

The Company applies the ten corporate governance principles contained in the Belgian Code on Corporate Governance and complies with the corporate governance provisions set out therein. If the Company has not complied with one or more provisions of the Belgian Code on Corporate Governance, it shall explain the reasons for not having done so in the corporate governance statement which is part of the Company's annual report.

What constitutes good corporate governance will evolve with the changing circumstances of a company and with the standards of corporate governance globally, and must be tailored to meet those changing circumstances. The board of directors of the Company intends to update this Charter as often as required to reflect changes to the Company's corporate governance.

The current version of this Charter was approved by the Company's board of directors on 21 April 2023. The board of directors of the Company will review this Charter from time to time and make such changes as it deems necessary and appropriate.

2. GENERAL INFORMATION

2.1. Company

The Company is a limited liability company organised in the form of a *naamloze vennootschap/société anonyme* under the laws of Belgium. The Company is registered with the legal entities register (Ghent, section Ghent) under enterprise number 0707.821.866. The Company's registered office is located at Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium.

2.2. Group structure

The Company is the parent company of the Sequana Medical group. Further information on the Company's group structure and its shareholders can be found on the Company's website (www.sequanamedical.com).

2.3. Available information

The Company has filed its deed of incorporation and must file its restated articles of association and all other deeds and resolutions that are to be published in the Annexes to the Belgian Official Gazette (*Belgisch Staatsblad/Moniteur Belge*) with the clerk's office of the commercial court of Ghent, section Ghent, where they are available to the public. The Company is registered with the legal entities register (Ghent, section Ghent) under enterprise number 0707.821.866. A copy of the Company's most recent articles of association and this Charter are also available on its website free of charge (www.sequanamedical.com).

In accordance with Belgian law, the Company must prepare annual audited statutory and consolidated financial statements. The annual statutory and consolidated financial statements and the reports of the Company's board of directors and statutory auditor relating thereto must

be filed with the National Bank of Belgium, where they are available to the public. Furthermore, as a company with shares listed on the regulated market of Euronext Brussels, the Company is also required to publish an annual financial report (which includes its audited statutory and consolidated financial statements, the report of its board of directors and the report of the statutory auditor) and an annual announcement preceding the publication of the annual financial report, as well as a half-yearly financial report on the first six months of its financial year (which includes a condensed set of financial statements and an interim management report). Copies of these documents will be made available on the Company's website and on STORI, the Belgian central storage mechanism, which is operated by the Belgian Financial Services and Markets Authority ("**FSMA**") and can be accessed via stori.fsma.be or www.fsma.be.

The Company must also disclose inside information (price sensitive information), information about its shareholder structure and certain other information to the public in accordance with applicable law. In accordance with the Belgian Royal Decree of 14 November 2007 on the obligations of issuers of financial instruments that are admitted to trading on a regulated market and Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (the "**Market Abuse Regulation**") and related rules, as amended from time to time, such information and documentation will be made available through the Company's website, press releases, the communication channels of Euronext Brussels, on STORI, or a combination of these means. All press releases published by the Company are also made available on its website.

3. BOARD OF DIRECTORS

3.1. Governance structure

The Company has opted for a "one tier" governance structure whereby the board of directors is the ultimate decision making body, with the overall responsibility for the management and control of the Company, and is authorised to carry out all actions that are considered necessary or useful to achieve the Company's purpose. The board of directors has all powers except for those reserved to the general shareholders' meeting by law or the Company's articles of association. The board of directors acts as a collegiate body.

3.2. Powers and responsibilities

Pursuant to this Charter, the role of the board of directors is to pursue sustainable value creation by the Company, by determining the Company's strategy, putting in place effective, responsible and ethical leadership, and monitoring the Company's performance.

In order to effectively pursue such sustainable value creation, the board will attempt to develop an inclusive approach that balances the legitimate interests and expectations of shareholders and other stakeholders. The board should support the executive management in the fulfilment of their duties and should be prepared to constructively challenge the executive management whenever appropriate. The board members should be available to give advice, also outside of board meetings.

(a) As to strategy, the board is responsible for:

- deciding on, and regularly reviewing, the Company's medium and long-term strategy based on proposals from the executive management;
- approving the operational plans and main policies developed by the executive management to give effect to the approved Company strategy;
- ensuring that the Company's culture is supportive of the realization of its strategy and that it promotes responsible and ethical behaviour;

- determining the risk appetite of the Company in order to achieve the Company's strategic objectives.
- (b) As to leadership, the board is responsible for:
- appointing and dismissing the chief executive officer and the other members of the executive management, in consultation with the chief executive officer, and taking into account the need for a balanced executive team;
 - ensuring that there is a succession plan in place for the chief executive officer and the other members of the executive management, and reviewing this plan periodically;
 - determining the Company's remuneration policy for non-executive board members and members of the executive management, taking into account the overall remuneration framework of the Company;
 - annually reviewing the executive management's performance and the realization of the Company's strategic objectives against agreed performance measures and targets;
 - making proposals to the shareholders' meeting for the appointment or re-appointment of board members and ensuring that there is a succession planning for board members in place.
- (c) As to monitoring, the board is responsible for:
- approving the framework for internal control and risk management proposed by the executive management and reviewing the implementation of this framework;
 - taking all necessary measures to ensure the integrity and timely disclosure of the Company's financial statements and other material financial and non-financial information in accordance with applicable law;
 - ensuring that the Company presents an integrated view of the Company's performance in its annual report, and that the annual report contains sufficient information on issues of importance for society and on relevant environmental and social indicators;
 - ensuring that there is a process in place for monitoring the Company's compliance with laws and other regulations, as well as for the application of internal guidelines relating thereto;
 - approving a code of conduct (or several activity-specific codes of conduct), setting out the expectations for the Company's leadership and employees in terms of responsible and ethical behaviour. The board should monitor compliance with such code of conduct at least on an annual basis.

The board of directors is assisted by a number of committees in relation to specific matters. The committees advise the board of directors on these matters, but the decision making remains with the board of directors as a whole.

3.3. Composition

Pursuant to the Belgian Companies and Associations Code and the Company's articles of association, the board of directors must consist of at least three directors.

The composition of the board of directors should ensure that decisions are made in the corporate interest. The composition of the board should be determined so as to gather sufficient expertise

in the Company's areas of activity as well as sufficient diversity of skills, background, age and gender.

Pursuant to the Belgian Code on Corporate Governance, at least half of the directors must be non-executive directors, and the board should consist of an appropriate number of independent directors. At least three directors should qualify as independent directors in accordance with the criteria described in the Belgian Code on Corporate Governance (see below). By 1 January 2025, at least one third of the members of the board of directors must be of the opposite gender. On the date of this Charter, the Company's board of directors complies with this requirement.

The directors are appointed for a term of no more than four years by the shareholders' meeting. They may be re-elected for a new term. Proposals to the shareholders' meeting for the appointment or re-election of any director must be accompanied by a recommendation from the board. In the event the office of a director becomes vacant, the remaining directors can appoint a successor temporarily filling the vacancy until the next general shareholders' meeting. The general shareholders' meeting can dismiss the directors at any time.

Adequacy of size and composition will be regularly assessed by the board of directors upon the initiative of the chairperson and upon recommendation of the remuneration and nomination committee.

All members of the board of directors should uphold the highest standards of integrity and probity.

3.4. Chairperson

An important function within the board of directors is reserved to the chairperson, who leads the board of directors, takes measures to engender a climate of trust, allowing for open discussions and constructive challenge, and supervises the good and efficient functioning of the board of directors.

The chairperson should be a person trusted for his, her or its professionalism, independence of mind, coaching capabilities, ability to build consensus, and communication and meeting management skills. The board of directors elects a chairperson from among its non-executive members on the basis of his, her or its knowledge, skills, experience and mediation strength. The chairperson of the board of directors and the chief executive officer should not be the same individual. If the board envisages appointing a former chief executive officer as chairperson, it should carefully consider the positive and negative implications of such a decision and disclose in the corporate governance statement why such appointment will not hamper the required autonomy of the chief executive officer.

The chairperson determines the calendar and the agenda of the meetings of the board of directors in consultation with the chief executive officer and the company secretary. The agenda should specify which topics are for information, for deliberation or for decision-making purpose. He, she or it should ensure that procedures relating to preparatory work, deliberations, the passing of resolutions and the implementation of decisions are properly followed and that the directors are provided with accurate, concise, timely and clear information before the meetings and, where necessary, between meetings, so that they can make a knowledgeable and informed contribution to board discussions. All board members should receive the same board information. He, she or it leads the meetings of the board of directors and ensures that there is sufficient time for consideration and discussion before decision-making. Once decisions are taken, all board members should be supportive of their execution.

The chairperson should establish a close relationship with the chief executive officer, providing support and advice, and should ensure effective interaction between the board and the executive management.

The chairperson should ensure effective communication with shareholders and that board members develop and maintain an understanding of the views of the shareholders and other significant stakeholders.

The chairperson, or if the chairperson is absent, the vice- chairperson, or if the vice- chairperson is absent, a director appointed by the other present directors, shall lead the meetings of the board of directors.

3.5. Independent directors

A director will only qualify as an independent director if he, she or it does not have a relationship with the Company or an important shareholder of the Company which jeopardises his, her or its independence. In case the director is a legal entity, the independence of such director must be assessed both for the legal entity as for its permanent representative. In order to assess whether a candidate director meets the aforementioned condition, the criteria set out in provision 3.5 of the Belgian Code on Corporate Governance will be applied. These criteria can be summarised as follows:

1. Not being an executive member of the board of directors or exercising a function as a member of the executive management or as a person entrusted with the daily management of the Company or a company or person affiliated with the Company, and not having been in such a position during the three years before his, her or its appointment. Alternatively, no longer enjoying share options of the Company related to such position.
2. Not having served for a total term of more than twelve years as a non-executive member of the board of directors.
3. Not being part of the senior management (as defined in Article 19, 2° of the Belgian Act of 20 September 1948 regarding the organization of the business industry) of the Company or a company or person affiliated with the Company, and not having been in such a position for the three years before his, her or its appointment. Alternatively, no longer enjoying share options of the Company related to such position.
4. Not receiving, or having received during their mandate or for a period of three years prior to their appointment, any significant remuneration or any other significant advantage of a patrimonial nature from the Company or a company or person affiliated with the Company, other than any fee he, she or it receives or has received as non-executive director.
5. (a) Not holding (either directly or indirectly, either alone or acting in concert) any shares representing in total one tenth or more of the Company's capital or one tenth or more of the voting rights in the Company at the moment of appointment; (b) In no event been nominated by a shareholder meeting the conditions described under (a).
6. Not having, or having had within the previous year before their appointment, a significant business relationship with the Company or a company or person affiliated with the Company, either directly or as partner, shareholder, member of the board of directors or member of the senior management (as defined in Article 19, 2° of the aforementioned Belgian Act of 20 September 1948) of a company or person who maintains such a relationship.
7. Not be or have been within the last three years before their appointment, a partner or member of the audit team of the Company or the person who is, or has been within the last three years before their appointment, the statutory auditor of the Company or an affiliated company or person.
8. Not be an executive of another company in which a member of the executive management of the Company is a non-executive member of the board, and not having other significant links with executive directors of the Company through involvement in other companies or bodies.

9. Not have, in the Company or an affiliated company or person, a spouse, legal partner or close family member to the second degree, exercising a function as board member or executive or person entrusted with the daily management or member of the senior management (as defined in Article 19, 2° of the aforementioned Belgian Act of 20 September 1948) or falling in one of the other circumstances referred to in 1. to 8. above, and as far as point 2. is concerned, up to three years after the date on which the relevant relative has terminated his, her or its last term.

In case the board of directors proposes a candidate director who does not meet the above criteria to the shareholders' meeting for appointment as independent director, it will set out the reasons why it deems that the candidate is independent.

The board of directors will disclose in its annual report which directors it considers to be independent directors. An independent director who ceases to satisfy the requirements of independence must immediately inform the board of directors thereof via the chairperson of the board.

3.6. Company secretary

The board of directors appoints a secretary who has the necessary skills and knowledge of corporate governance matters.

The role of the secretary includes supporting the board and its committees on all governance matters, preparing the Charter and the corporate governance statement, ensuring a good information flow within the board and its committees and between the executive management and the non-executive board members, drafting the minutes of the board meetings (ensuring that the essence of the discussions and decisions at board meeting are accurately captured), and facilitating induction and assisting with professional development of directors as required. Individual board members should have access to the company secretary.

3.7. Third parties

At the request of any director and subject to the approval of the board of directors, any third party (including employees and advisors) may be invited to attend the whole or any part of a meeting of the board of directors, in a consultative capacity. Persons attending the meetings in a consultative capacity have no voting rights.

3.8. Organisation of meetings

The board should function as a collegial body. No individual or group of board members should dominate the board's decision-making.

The board of directors shall meet as frequently as the interest of the Company requires., or at the request of one or more directors. The board of directors will meet sufficiently regularly to discharge its duties effectively, and at least five (5) times per year. The date, hour and place of these meetings are agreed upon by the board of directors, upon a proposal by the chairperson, for the next financial year at the last meeting of each financial year. Additional meetings may be called by any director upon at least five (5) business days notice. Non-executive board members should meet at least once a year in the absence of the chief executive officer and the other members of the executive management.

The meetings of the board of directors are held at the registered office of the Company or at any other place indicated in the convening notice. The Company may organise – where necessary and appropriate – board meetings using video, telephone or internet-based means.

Unless all directors agree otherwise, convening notices must be given at least four (4) calendar days before the meeting, except in case of emergency. In case of emergency, the convening

notice must be given with not less than two (2) business days, and the reasons for the emergency should be specified in the notice.

Convening notices are valid if delivered by letter, fax, e-mail or any other means of communication permitted by applicable law. The convening notice must be accompanied by an agenda of the business to be transacted at such meeting together with all relevant documentation and information relating thereto. The documentation and information to be sent with the agenda must be sent to all directors.

The board of directors can only deliberate and resolve on items included in the agenda. The board of directors can only validly deliberate on items that are not mentioned on the agenda, if all directors are present or represented at the meeting and unanimously consent to do so. This consent is assumed to have been given if no objection is recorded in the minutes.

Each director can instruct, by means of an ordinary letter, telegram, telex, fax, e-mail or any other means of communication or medium bearing his/her/its signature (including an electronic signature to the extent allowed as written evidence by the applicable legislation), another director to represent him or her at a specified meeting of the board of directors and to vote in his/her/its place. In that case, the instructing director shall be deemed present. A director can represent multiple members of the board of directors and can, in addition to his/her/its own vote, cast as many votes for which he/she/it has a proxy.

In principle, directors should attend board meetings in person. If this is not possible, they may use any telecommunication means permitting a joint discussion, such as telephone conferencing or video conferencing. Directors taking part in a meeting held by conference call or video conference shall be deemed present at the meeting.

The resolutions of the board of directors can be taken by unanimous written resolutions of all directors.

Decisions are made by a simple majority of the votes cast. The chairperson has no casting vote.

The company secretary drafts minutes of each meeting reflecting the issues which were discussed and the decisions which were taken. The minutes are approved by the chairperson and subsequently by the board of directors during its next meeting. The minutes are signed at least by the chairperson of the board, as well as by the directors who so request, and are kept at the registered office of the Company. The minutes of the meeting should summarise the discussions, specify the decisions taken and note diverging views expressed by board members. The names of the intervening board members should only be recorded if specifically requested by them.

3.9. Remuneration of the directors

The board of directors should adopt, upon the advice of the remuneration and nomination committee, a remuneration policy designed to (i) attract, reward and retain the necessary talent, (ii) promote the achievement of strategic objectives in accordance with the Company's risk appetite and behavioural norms, and (iii) to promote sustainable value creation.

The board of directors should make sure that the remuneration policy is consistent with the overall remuneration framework of the Company, as well as the provisions of the Belgian Code on Corporate Governance and the Belgian Companies and Associations Code.

The board of directors should submit the policy to the general shareholders' meeting. When a significant proportion of the votes have been cast against the remuneration policy, the Company should take the necessary steps to address the concerns of those voting against it, and consider adapting its remuneration policy.

The remuneration principles with respect to the directors are set out in the Company's remuneration policy. The remuneration of the directors for a certain financial year is included in the corporate governance statement which is part of the Company's annual report.

The Company also reimburses reasonable out of pocket expenses of directors (including travel expenses) incurred in performing the activity of director. Without prejudice to the powers granted by law to the general shareholders' meeting, the board of directors sets and revises the rules for reimbursement of directors' business-related out of pocket expenses.

3.10. Indemnification and insurance of directors

The Company, acting through the board of directors, can, to greatest extent permitted by applicable law, enter into indemnification and hold harmless arrangements with the directors and agents of the Company and its subsidiaries, and take out insurance coverage in order to cover liability of the directors and agents of the Company and its subsidiaries.

3.11. Right of information and inspection

Each member of the board of directors may request information about all matters concerning the Company.

During the meetings, any director may request information from the other members of the board of directors.

Between meetings, each director may request the chairperson of the board of directors information concerning the Company's business and specific matters. Each board member is entitled to request independent professional advice in the framework of the performance of his, her or its mandate as director, at the Company's expense. Such request must be made to, and approved by, the chairperson.

Each director is entitled to visit, upon reasonable notice, the Company's premises, and examine on site Company data and other records, including corporate records and financial books and accounts and, to discuss the Company's business and finances with members of the Company's executive management.

The right of access to information is subject, in the case of personal information concerning employees of the Company, to applicable privacy laws. Directors may only use the information they receive for the purpose of exercising their duties and must preserve the confidentiality of such information.

3.12. Confidentiality

Directors and, as the case may be, other persons attending meetings of the board of directors must deal carefully with confidential information that they receive in their capacity as director or advisor. They may only use such confidential information in the framework of their mandate as director, or capacity as advisor, of the Company.

3.13. Conflicts of interest

Each director should place the Company's interests above his, her or its own interests. The directors have the duty to look after the interests of all shareholders on an equivalent basis. Each board member should act in accordance with the principles of reasonableness and fairness.

When the board of directors takes a decision, board members should disregard their personal interests. They should not use business opportunities intended for the Company for their own benefit.

The directors are deemed to avoid, to the extent possible, to perform any actions, to defend certain positions, and to pursue certain interests, if this would conflict, or would give the impression to conflict, with the interests of the Company. Each board member should, in particular, be attentive to conflicts of interests that may arise between the Company, its board members, its significant or controlling shareholder(s) and other shareholders. The board members who are proposed by significant or controlling shareholder(s) should ensure that the interests and intentions of these shareholder(s) are sufficiently clear and communicated to the board in a timely manner.

If a conflict of interest could occur, the director concerned shall immediately inform the board thereof at the beginning of the meeting. The board should, under the lead of its chairperson, decide which procedure it will follow to protect the interests of the Company and its shareholders. In the next annual report, the board should explain why they chose this procedure. However, where there is a substantial conflict of interests, the board should carefully consider communicating as soon as possible on the procedure followed, the most important considerations and the conclusions.

In the event of a conflict of interest within the meaning of Article 7:96 and/or 7:97 of the Belgian Companies and Associations Code, the director must in any event comply with the applicable legal provisions of the Belgian Companies and Associations Code and the articles of association of the Company, and, more in particular, bring it to the attention of both the statutory auditor and fellow directors and abstain from deliberation and voting on the transaction in which the conflict situation arises. If all directors have a conflict of interest, the decision or the transaction shall be submitted to the general shareholders' meeting. If the general shareholders' meeting approves the decision or the transaction, the board of directors may execute it.

Transactions and/or business relationships between directors and one or more companies of the Sequana Medical group, even if these transactions do not strictly fall within the scope of application of Article 7:96 and/or 7:97 of the Belgian Companies and Associations Code, should always take place at normal market conditions. The director concerned must inform the chairperson of the board of directors in advance of such transactions.

The board should act in such a manner that a conflict of interests, or the appearance of such a conflict, is avoided.

3.14. Integrity and independence of mind

Board members should engage actively in their duties and should be able to make their own sound, objective and independent judgements when discharging their responsibilities. Acting with independence of mind includes developing a personal conviction and having the courage to act accordingly by assessing and challenging the views of other board members, by interrogating the members of the executive management when appropriate in the light of the issues and risks involved, and by being able to resist group pressure.

Board members should make sure they receive detailed and accurate information and should spend sufficient time studying it carefully so as to acquire and maintain a clear understanding of the key issues relevant to the company's business. Board members should seek clarification whenever they deem it necessary.

Board members should not use the information obtained in their capacity as a board member for purposes other than for the exercise of their mandate. Board members should handle the confidential information received in their capacity as a board member with utmost care.

Board members should communicate to the board any information in their possession that could be relevant to the board's decision-making. In the case of sensitive or confidential information, board members should consult the chairperson.

3.15. Evaluation

The board of directors will evaluate, through a formal process and at least every three years, its own performance and its interaction with the executive management, as well as its size, composition, and functioning and that of its committees. The evaluation assesses how the board of directors and its committees operate, checks that important issues are effectively prepared and discussed, evaluates each director's contribution and constructive involvement, and assesses the present composition of the board of directors and its committees against the desired composition. This evaluation takes into account the members' general role as director, and specific roles as chairperson, chairperson or member of a committee of the board of directors, as well as their relevant responsibilities and time commitment.

At the end of each board member's term, the remuneration and nomination committee should evaluate this board member's presence at the board or committee meetings, their commitment and their constructive involvement in discussions and decision-making in accordance with a pre-established and transparent procedure. The remuneration and nomination committee should also assess whether the contribution of each board member is adapted to changing circumstances. -

The board will act on the results of the performance evaluation. Where appropriate, this will involve proposing new board members for appointment, proposing not to re-appoint existing board members or taking any measure deemed appropriate for the effective operation of the board.

3.16. Other mandates

Non-executive board members should not take on more than five board memberships in listed companies. Changes to their other relevant commitments and their new commitments outside the Company should be reported to the chairperson of the board as they arise.

3.17. Special committees

The board of directors should set up specialised committees in order to advise the board in respect of decisions to be taken, to give comfort to the board that certain issues have been adequately addressed and, if necessary, to bring specific issues to the attention of the board. The decision-making should remain the collegial responsibility of the board of directors.

Each committee should meet sufficiently regularly to execute its duties effectively. The Company may organise – where necessary and appropriate – committee meetings using video, telephone or internet-based means.

The board of directors determines the terms of reference of each committee with respect to the organization, procedures, policies and activities of the committee. The board of directors appoints the members of each committee. Each committee must be composed of at least three board members subject to the provisions of the Belgian Code on Corporate Governance and applicable legislation. Only directors can be member of a specialised committee, and their appointment cannot be for a term longer than their mandate as director. Members of the executive and senior management may be invited to attend committee meetings to provide relevant information and insights into their areas of responsibility. Each committee should be entitled to meet with any relevant person without any executive being present. Each committee is entitled to request independent professional advice in the framework of the performance of its roles, at the Company's expense.

The board of directors should ensure that each committee, as a whole, has a balanced composition and has the necessary independence, skills, knowledge, experience and capacity to execute its duties effectively. The board should ensure that a chairperson is appointed for each committee.

Strategy formulation should not be referred to any permanent committee.

After each committee meeting, the board of directors should receive a written report on its findings and recommendations ('minutes') from each committee and oral feedback from each committee at the next board meeting.

The board of directors has established, in its midst and under its responsibility, two board committees which are responsible for assisting the board of directors and making recommendations in specific fields: an audit committee (in accordance with Article 7:119 of the Belgian Companies and Associations Code and provision 4.10 of the Belgian Code on Corporate Governance) and a remuneration and nomination committee (in accordance with article 7:120 of the Belgian Companies and Associations Code and provision 4.17 of the Belgian Code on Corporate Governance).

4. AUDIT COMMITTEE

4.1. Role of the audit committee

The role of the audit committee is to assist the board of directors in fulfilling its monitoring responsibilities in respect of control in the broadest sense (including risks) by supervising and reviewing the financial reporting process, the internal control and risk management systems and the internal audit process of the Company.

In particular, the audit committee will:

- inform the board of directors of the result of the audit of the financial statements and the manner in which the audit has contributed to the integrity of the financial reporting and the role that the audit committee has played in that process;
- monitor the financial reporting process, and to make recommendations or proposals to ensure the integrity of the process;
- monitor the effectiveness of the internal control and risk management systems, and the Company's internal audit process and its effectiveness;
- monitor the audit of the financial statements, including the follow-up questions and recommendations by the statutory auditor;
- assess and monitor the independence of the statutory auditor, in particular with respect to the appropriateness of the provision of additional services to the Company. More specifically, the audit committee analyses, together with the statutory auditor, the threats for the statutory auditor's independence and the security measures taken to limit these threats, when the total amount of fees exceeds the criteria specified in article 4 §3 of Regulation (EU) No 537/2014; and
- make recommendations to the board of directors on the selection, appointment and remuneration of the statutory auditor of the Company in accordance with article 16 § 2 of Regulation (EU) No 537/2014.

The audit committee regularly reports to the board of directors on the exercise of its missions, and at least when the board of directors approves the financial statements and the condensed or short form financial information that will be published. The members of the audit committee have full access to the executive management and to any other employee to whom they may require access in order to carry out their responsibilities.

The committee is an advisory body only and the decision-making remains within the collegial responsibility of the board of directors.

Without prejudice to the statutory provisions which determine that the statutory auditor must address reports or warnings to the corporate bodies of the Company, the statutory auditor must discuss, at the request of the statutory auditor, or at the request of the audit committee or of the board of directors, with the audit committee or with the board of directors, essential issues which are brought to light in the exercise of the statutory audit of the financial statements, which are included in the additional statement to the audit committee, as well as any meaningful shortcomings discovered in the internal financial control system of the Company.

4.2. Composition of the audit committee

The members of the committee are appointed by the board of directors. They can be removed by the board of directors at any time. Only directors can be members of the committee, and the term of their mandates as members of the committee cannot be longer than the term of their respective mandates as director.

The audit committee consists of at least three directors. According to the Belgian Companies Code, all members of the audit committee must be non-executive directors, and at least one member must be independent. The members of the audit committee must have a collective competence in the business activities of the Company as well as in accounting, auditing and finance, and at least one member of the audit committee must have the necessary competence in accounting and auditing.

The chairperson of the audit committee is to be appointed by the members of the audit committee.

4.3. Organisation of meetings

4.3.1. Scheduling of meetings

At the beginning of the financial year, the chairperson of the committee will establish a schedule and agenda of subjects to be discussed during the year (to the extent that this can be foreseen). The audit committee shall meet whenever it deems it necessary for the proper performance of its duties and at least four (4) regularly scheduled meetings each year. At least twice (2) a year, the committee should meet the external and internal auditors (if applicable), to discuss matters relating to its terms of reference and any issues arising from the audit process. Additional unscheduled meetings of the committee may be called upon at any time when the committee deems this necessary or upon the request of any member of the committee.

4.3.2. Convening of meetings

The meetings are convened by the chairperson of the committee. The chairperson will establish the agenda for each meeting of the committee. Each member is encouraged to suggest the inclusion of items on the agenda at any time. The agenda lists the topics to be discussed. If the chairperson of the committee does not convene the meeting within seven (7) days following the request to call a meeting by another member, the latter member can convene the meeting.

The notice to convene a meeting of the committee must mention the place, date, hour and agenda of the meeting, and must be sent to the members at least four (4) business days prior to the meeting. The due convening of a meeting cannot be challenged if all members are present or represented at the meeting.

Information that is important to the understanding of the committee of the business to be conducted at a meeting of the committee is distributed in writing to the members before the meeting.

4.3.3. Attendance and quorum

Meetings are held in person. Members that cannot be present at the meeting, can attend meetings via conference call, video conference or other communication means, provided that all members can communicate with each other.

The meetings of the audit committee are chaired by its chairperson. In the absence of the chairperson, the meetings are chaired by another member.

The committee decides whether, and if so, when the chief executive officer, the chief financial officer (or senior employees responsible for finance, accounting, and treasury matters), the internal auditor and the statutory auditor may take part in the meeting in an advisory and consulting capacity only. The committee is entitled to meet with any relevant person without any member of the executive management present.

The committee can only validly deliberate and resolve on matters that are included on the agenda of the meeting if at least two of the members are present at the meeting. On matters that are not included on the agenda of the meeting, the meeting of the committee can only validly deliberate and resolve if all members of the committee are present or represented at the meeting and agree to deliberate and resolve on such matters.

Each member can give a power of attorney to another member to represent him or her at a meeting.

All decisions within the committee require a simple majority of the votes cast at a validly convened and quorate meeting. In case the votes are tied, the director chairing the committee has a casting vote.

4.4. Access to information

The members of the committee should have unrestricted access to the offices and all information and papers kept by the Company and its subsidiaries (from time to time). The members of the audit committee have full access to the executive management and to any other employee to whom they may require access in order to carry out their responsibilities. When requesting such information, each member must inform the other members of the committee thereof and exchange such information with the other members of the committee. Where practical or appropriate such requests will be channelled through the chairperson of the board of directors.

The committee can have access to external advisors.

4.5. Reporting to the board of directors

The committee must prepare reports of its findings and recommendations. Such reports should be submitted to the board of directors as soon as practically possible after each meeting of the committee.

The committee should regularly report to the board of directors on its operations, findings and recommendations, and at least once a year prior to the approval of the annual financial statements and annual report by the board of directors.

The other members of the board of directors have access to the working papers of the committee. Where practical or appropriate, requests to have such access are made via the chairperson of the committee.

4.6. Evaluation

The committee annually reviews its terms of reference and its own effectiveness and, if necessary, recommends changes to the board of directors.

5. REMUNERATION AND NOMINATION COMMITTEE

5.1. Role of the remuneration and nomination committee

The role of the remuneration and nomination committee is to make recommendations to the board of directors with regard to the appointment and remuneration of directors and members of the executive management and, in particular, to:

- identify, recommend and nominate, for the approval of the board of directors, candidates to fill vacancies in the board of directors and executive management positions as they arise. In this respect, the remuneration and nomination committee must consider and advise on proposals made by relevant parties, including management and shareholders;
- advise the board of directors on any proposal for the appointment of the chief executive officer and on the chief executive officer's proposals for the appointment of other members of the executive management;
- draft appointment procedures for members of the board of directors and the chief executive officer;
- ensure that the appointment and re-election process is organised objectively and professionally;
- periodically assess the size and composition of the board of directors and make recommendations to the board of directors with regard to any changes;
- prepare plans for the orderly succession of board members. The remuneration and nomination committee should lead the re-appointment process of board members;
- ensure that sufficient and regular attention is paid to the succession of members of the executive management;
- ensure that appropriate talent development programmes and programmes to promote diversity in leadership are in place;
- make proposals to the board of directors on the remuneration policy for directors and members of the executive management and the persons responsible for the day-to-day management of the Company, as well as, where appropriate, on the resulting proposals to be submitted by the board of directors to the shareholders' meeting;
- make proposals to the board of directors on the individual remuneration of directors and members of the executive management, and the persons responsible for the day-to-day

management of the Company, including variable remuneration and long-term incentives, whether or not share-related, in the form of share options or other financial instruments, and arrangements on early termination, and where applicable, on the resulting proposals to be submitted by the board of directors to the shareholders' meeting;

- prepare a remuneration report to be included by the board of directors in the annual corporate governance statement;
- present and provide explanations in relation to the remuneration report at the annual shareholders' meeting; and
- report regularly to the board of directors on the exercise of its duties.

The committee is an advisory body only and the decision-making remains the collegial responsibility of the board of directors. In principle, the remuneration and nomination committee meets as frequently as necessary for carrying out its duties, but at least two times a year.

At least once a year, the committee evaluates the operation and performance of the members of the executive management in accordance with a clearly specified set of evaluation criteria. The chief executive officer attends the evaluations of all members of the executive management other than himself.

5.2. Composition of the remuneration and nomination committee

The members of the committee are appointed by the board of directors. They can be removed by the board of directors at any time. Only directors can be members of the committee, and the term of their mandates as members of the committee cannot be longer than the term of their respective mandates as director.

The remuneration and nomination committee consists of at least three directors. In line with the Belgian Companies and Associations Code and the Belgian Code on Corporate Governance (i) all members of the remuneration and nomination committee are non-executive directors, (ii) the remuneration and nomination committee consists of a majority of independent directors and (iii) the remuneration and nomination committee is chaired by the chairperson of the board of directors or another non-executive director appointed by the committee.

Pursuant to the Belgian Companies and Associations Code, the remuneration and nomination committee must have the necessary expertise in terms of remuneration policy, which is evidenced by the experience and previous roles of its current members.

The chief executive officer participates in the meetings of the remuneration and nomination committee in an advisory capacity each time the remuneration of another member of the executive management is being discussed.

5.3. Organisation of meetings

5.3.1. Scheduling of meetings

At the beginning of the financial year, the chairperson of the committee will establish a schedule and agenda of subjects to be discussed during the year (to the extent that this can be foreseen). The committee should have at least two (2) scheduled meetings each year. Additional unscheduled meetings of the committee may be called upon at any time when the committee deems this necessary or upon the request of any member of the committee.

5.3.2. Convening of meetings

The meetings are convened by the chairperson of the committee. The chairperson will establish the agenda for each meeting of the committee. Each member is encouraged to suggest the inclusion of items on the agenda at any time. The agenda lists the topics to be discussed. If the chairperson of the committee does not convene the meeting within seven (7) days following the request to call a meeting by another member, this member can convene the meeting.

The notice to convene a meeting of the committee must mention the place, date, hour and agenda for the meeting, and must be sent to the members at least four (4) business days prior to the meeting. The due convening of a meeting cannot be challenged if all members are present or represented at the meeting.

Information that is important to the understanding of the committee of the business to be conducted at a meeting of the committee is distributed in writing to the members before the meeting.

5.3.3. Attendance and quorum

Meetings are held in person. Members that cannot be present at the meeting, can attend meetings via conference call, video conference or other communication means, provided that all members can communicate with each other.

The meetings of the committee are chaired by its chairperson. In the absence of the chairperson, the meetings are chaired by another member.

The committee can only validly deliberate and resolve on matters that are included on the agenda of the meeting if at least two of the members are present at the meeting. On matters that are not included on the agenda of the meeting, the meeting of the committee can only validly deliberate and resolve if all members of the committee are present or represented at the meeting and agree to deliberate and resolve on such matters.

Each member can give a power of attorney to another member to represent him or her at a meeting.

All decisions within the committee require a simple majority of the votes cast at a validly convened and quorate meeting. In case the votes are tied, the director chairing the committee has a casting vote.

5.4. **Access to information**

The committee can have access to external advisors.

5.5. **Reporting to the board of directors**

The committee will prepare reports of its findings and recommendations. Such reports should be submitted to the board of directors as soon as practically possible after each meeting of the committee.

The committee should regularly report to the board of directors on its operations, findings and recommendations, and at least once a year prior to the approval of the annual financial statements and annual report by the board of directors.

The other members of the board of directors have access to the working papers of the committee. Where practical or appropriate, requests to have such access are made via the chairperson of the committee.

5.6. Specific guidelines

The members of the committee must treat the information of executive management in a confidential manner. When dealing with their own remuneration package, members must abstain from deliberations and resolutions within the committee. They must report such conflict of interest to the chairperson of the board of directors and the chairperson of the committee.

5.7. Evaluation

The committee should annually review its terms of reference and its own effectiveness and, if necessary, recommend changes to the board of directors.

6. EXECUTIVE MANAGEMENT

6.1. Members of the executive management

The executive management is composed of two (2) members and is led by the chief executive officer. Its members are appointed by the board of directors on the basis of a recommendation by the remuneration and nomination committee. The executive management is responsible and accountable to the board of directors for the discharge of its responsibilities.

6.2. Chief executive officer

The board of directors appoints and removes the chief executive officer and determines the powers of the chief executive officer.

The chief executive officer is responsible for the day-to-day management of the Company and the implementation of the Company's mission, its strategy and the targets set by the board of directors, with a focus on the long-term future growth of the business. He, she or it has direct operational responsibility for the Company and oversees the organisation and day-to-day management of subsidiaries, affiliates and joint ventures. The chief executive officer is responsible for the execution and management of the outcome of all decisions of the board of directors.

The chief executive officer leads the executive management within the framework established by the board of directors and under its ultimate supervision. The chief executive officer is appointed and removed by the board of directors and reports directly to it.

6.3. Day-to-day management

The board of directors has delegated the day-to-day management of the Company as well as certain other management and operational powers to the chief executive officer. The chief executive officer is assisted by the chief financial officer and the other members of the executive management.

6.4. Responsibilities of the executive management

The board of directors determines the powers and duties entrusted to the executive management and develops a clear delegation policy, in close consultation with the chief executive officer. The executive management will at least:

- formulate proposals to the board in relation to the Company's strategy and its implementation;
- be entrusted with the operational leadership of the Company;

- propose a framework for internal control (*i.e.* systems to identify, assess, manage and monitor financial and other risks) and risk management, and put in place internal controls, without prejudice to the board's monitoring role, and based on the framework approved by the board of directors;
- present to the board of directors complete, timely, reliable and accurate financial statements, in accordance with the applicable accounting standards and policies of the Company;
- prepare the Company's mandatory disclosure of the financial statements and other material financial and non-financial information;
- present the board of directors with a balanced and understandable assessment of the Company's financial situation;
- prepare the Company's yearly budget to be submitted to the board of directors;
- timely provide the board of directors with all information necessary for it to carry out its duties;
- be responsible and accountable to the board of directors for the discharge of its responsibilities;
- implement the decisions made and the policies, plans and policies approved by the board and deal with such other matters as are delegated by the board of directors from time to time;
- report all key decisions taken by the executive management to the board of directors.

The executive management meets at least once a week in person or via telephone or other telecommunication means.

Interactions between members of the board of directors and members of the executive management should take place in a transparent way. The chairperson should always be informed.

6.5. Delegation of powers

The board of directors can from time to time delegate certain specific powers to one or more members of the executive management.

6.6. Remuneration

The board of directors should adopt, upon the advice of the remuneration and nomination committee, a remuneration policy designed to (i) attract, reward and retain the necessary talent, (ii) promote the achievement of strategic objectives in accordance with the Company's risk appetite and behavioural norms, and (iii) to promote sustainable value creation.

The remuneration of the chief executive officer and the other members of the executive management is based on recommendations made by the remuneration and nomination committee and is set out in the Company's remuneration policy. The chief executive officer participates in the meetings of the remuneration and nomination committee in an advisory capacity each time the remuneration of another member of the executive management is being discussed. The remuneration of the members of the executive management for a certain financial year is included in the corporate governance statement which is part of the Company's annual report.

6.7. Conflicts of interest

The members of the executive management are deemed to avoid, to the extent possible, to perform any actions, to defend certain positions, and to pursue certain interests, if this would conflict, or would give the impression to conflict, with the interests of the Company. If such conflicts of interest would occur, the concerned member of the executive management must immediately inform the chief executive officer hereof, who will in turn inform the board of directors.

To the extent relevant, the provisions relating to conflicts of interest of board members (see above) are *mutatis mutandis* applicable to members of the executive management.

Transactions and/or business relationships between members of the executive management and one or more companies of the Sequana Medical group must in any case take place at normal market conditions.

Members of the executive management can take on board mandates in other companies. New board mandates do however require the prior approval by the board of directors, which shall among others assess the risk for conflicts with such member's executive mandate within the Company. Time constraints and potential conflicts of interests should be considered and balanced against the opportunity for the executive's professional development. The existing mandates of the members of the executive management shall be subject to a regular assessment by the board of directors.

6.8. Integrity and independence of mind

To the extent relevant, the provisions relating to integrity and independence of mind of board members (see above) are *mutatis mutandis* applicable to members of the executive management.

6.9. Evaluation

The board of directors will evaluate the performance of the executive management and the realization of the Company's strategy against agreed performance measures and targets on a yearly basis, which will be based on a proposal by the remuneration and nomination committee. To the extent possible, the evaluation will be done during the first board meeting after the year of which the performance is evaluated.

7. SHARES AND SHAREHOLDERS

7.1. Overview shares and other securities

For an overview of the Company's outstanding shares and outstanding securities that are convertible or exercisable into shares, reference is made to the Company's website (www.sequanamedical.com).

7.2. Form of the shares

All of the shares belong to the same class of securities and are in registered or dematerialised form. A register of registered shares (which may be held in electronic form) is maintained at the Company's registered office. It may be consulted by any shareholder. A dematerialised share will be represented by an entry on a personal account of the owner or holder, with a recognised account holder or clearing and settlement institution. Shareholders may elect, at any time, to have their registered shares converted into dematerialised shares, and vice versa, at their own expense.

7.3. Transferability of the shares

The shares are freely transferable. This is without prejudice to certain restrictions that may apply pursuant to applicable securities laws.

7.4. Currency of the shares

The Company's shares do not have a nominal value, but each reflect an equal fraction of the Company's share capital, which is denominated in euro.

7.5. Voting rights attached to the shares

Each shareholder of the Company is entitled to one vote per share.

7.6. General shareholders' meetings

The Company encourages its shareholders to participate in general shareholders' meetings. In order to facilitate this, shareholders may vote in absentia by proxy. Agendas and all other relevant information are made available on the Company's website in advance of general shareholders' meetings.

7.7. Communication with shareholders and potential shareholders

The board will ensure an effective dialogue with shareholders and potential shareholders through appropriate investor relation programs, in order to achieve a better understanding of their objectives and concerns. Feedback of such dialogue will be given to the board, on at least an annual basis.

7.8. Notification of significant shareholdings

Pursuant to the Belgian Act of 2 May 2007 on the disclosure of significant shareholdings in issuers whose securities are admitted to trading on a regulated market and containing various provisions, as amended from time to time, a notification to the Company and to the FSMA is required by all natural persons and legal entities (i.e., legal person, enterprise without legal personality, or trust) in the following circumstances (non-exhaustive list):

- an acquisition or disposal of voting securities, voting rights or financial instruments that are treated as voting securities;
- the reaching of a threshold by persons or legal entities acting in concert;
- the conclusion, modification or termination of an agreement to act in concert;
- the downward reaching of the lowest threshold;
- the passive reaching of a threshold;
- the holding of voting securities in the Company upon first admission thereof to trading on a regulated market;
- where a previous notification concerning the financial instruments treated as equivalent to voting securities is updated;
- the acquisition or disposal of the control of an entity that holds voting securities in the Company; and

- where the Company introduces additional notification thresholds in the articles of association,

in each case where the percentage of voting rights attached to the securities held by such persons reaches, exceeds or falls below the legal threshold, set at 5% of the total voting rights, and 10%, 15%, 20% and so on in increments of 5% or, as the case may be, the additional thresholds provided in the articles of association. The Company has provided for additional thresholds of 3% in its articles of association.

The notification must be made promptly and at the latest within four trading days following the moment on which the person who is subject to the notification obligation received knowledge or could be deemed to have received knowledge of the acquisition or disposal of the voting rights triggering the reaching of the threshold. Where the Company receives a notification of information regarding the reaching of a threshold, it has to publish such information within three trading days following receipt of the notification.

Subject to certain exceptions, no shareholder may, pursuant to Article 25/1 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time, cast a greater number of votes at a general shareholders' meeting of the Company than those attached to the rights and securities that it has notified in accordance with the aforementioned disclosure rules at least 20 calendar days prior to the date of the general shareholders' meeting.

The forms on which such notifications must be made, as well as further explanations, can be found on the website of the FSMA (www.fsma.be). Violation of the disclosure requirements may result in the suspension of voting rights, a court order to sell the securities to a third party and/or criminal liability. The FSMA may also impose administrative sanctions.

The Company is required to publicly disclose any notifications received regarding increases or decreases in a shareholder's ownership of the Company's securities, and must mention these notifications in the notes to its financial statements. A list as well as a copy of such notifications will be accessible on the Company's website (www.sequanamedical.com).

7.9. Rules preventing market abuse

With a view to preventing market abuse (insider dealing, unlawful disclosure of inside information and market manipulation), the board of directors has established a dealing code. The dealing code describes the declaration and conduct obligations of directors, members of the executive management, certain other employees and certain other persons with respect to transactions in shares and other financial instruments of the Company. The dealing code sets limits on carrying out transactions in shares and other financial instruments of the Company and allows dealing by the aforementioned persons only during certain windows.

To implement and monitor the dealing code, the board of directors has designated a compliance officer whose responsibilities are set out in the dealing code.

The board of directors intends to take all necessary and useful measures for effective and efficient compliance with the applicable rules on market abuse.

8. MISCELLANEOUS

8.1. Changes to the Charter

The board of directors may amend this Charter from time to time without prior notice. It may also decide to deviate from this Charter subject to disclosure thereof in the corporate governance statement included in the Company's annual report. Third parties do not derive any rights from such modification or deviation.

8.2. Priority

In case of any contradiction between a provision of this Charter and an applicable mandatory law or regulation, such law or regulation supersedes the provision of this Charter.

8.3. Governing law

This Charter is governed by and construed in accordance with Belgian law.

SEQUANA MEDICAL DEALING CODE

12 February 2018

1. Introduction

Sequana Medical NV (the "**Company**") is a publicly listed limited liability company organised in the form of a *naamloze vennootschap/société anonyme* under the laws of Belgium. The Company is registered with the legal entities register (Ghent, division Ghent) under number 0707.821.866. The Company's registered office is located at AA Tower, Technologiepark 122, 9052 Ghent, Belgium.

The board of directors of the Company has adopted this Dealing Code (as defined below) with a view to preventing any acts of insider dealing (including recommending or inducing another person to engage in insider dealing), unlawful disclosure of inside information and market manipulation (together market abuse) by any Staff Member (as defined below) or by certain other persons with respect to the Company or the Company's shares or other financial instruments.

The rules on market abuse are mainly set out in Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended (the "**Market Abuse Regulation**") and its delegated and implementing EU regulations, as well as in the Belgian Act of 2 August 2002 on the supervision of the financial sector and the financial services. This Dealing Code sets out minimum standards to be followed and does not contain an exhaustive overview of all applicable rules on market abuse. All persons concerned must ensure at all times that they fully comply with all applicable rules on market abuse.

Failure to comply with this Dealing Code can result in administrative and/or criminal penalties, civil liability and disciplinary sanctions.

The FSMA is the competent authority in Belgium regarding the supervision on, and enforcement of, the applicable market abuse rules.

2. Definitions

In this Dealing Code, the following terms shall have the following meanings:

"**Sequana Medical**" means the Company together with each of its subsidiaries.

"**Closed Period**" means the period starting 30 calendar days before the announcement of the annual, half-yearly or, as the case may be, quarterly results (trading updates) of the Company, and ending at the close of the trading day on which such announcement is made.

"**Company**" has the meaning set out in Section 1 of this Dealing Code.

"**Compliance Officer**" means the chief financial officer of the Company or any other person designated from time to time by the board of directors of the Company to implement and monitor compliance with this Dealing Code.

"**Dealing Code**" means this set of rules adopted by the board of directors of the Company with a view to preventing market abuse.

"Financial Instrument" means a financial instrument as defined in point (15) of Article 4(1) of Directive 2014/65/EU of 15 May 2014 on markets in financial instruments, which includes, without being limited hereto:

- a) securities which are negotiable on the capital market, such as (i) shares, (ii) bonds or other forms of securitised debt, and (iii) any other securities giving the right to acquire or sell any securities mentioned under (i) or (ii) (e.g. securities exercisable or convertible into shares (such as warrants, share options, call options, convertible bonds and exchangeable bonds));
- b) options, futures, swaps, forward rate agreements and any other derivative contracts relating to securities.

"FSMA" means the Belgian Financial Services and Markets Authority.

"Market Abuse Regulation" has the meaning set out in Section 1 of this Dealing Code.

"Inside Information" has the meaning set out in Section **Error! Reference source not found.** of this Dealing Code.

"Person Closely Associated With" means:

- a) a spouse, or a partner considered to be equivalent to a spouse in accordance with national law;
- b) a dependent child, in accordance with national law;
- c) a relative who has shared the same household for at least one year on the date of the transaction concerned; or
- d) a legal person, trust or partnership, the managerial responsibilities of which are discharged by a PDMR or by a person referred to in point a), b) or c), or which is directly or indirectly controlled by such a person, or which is set up for the benefit of such a person, or the economic interests of which are substantially equivalent to those of such a person.

"Person Discharging Managerial Responsibilities" or **"PDMR"** means a person within the Company who is:

- a) a member of the board of directors or the executive management of the Company; or
- b) a senior executive who is not a member of the bodies referred to in point a), who has regular access to Inside Information relating directly or indirectly to the Company and power to take managerial decisions affecting the future developments and business prospects of the Company.

You will have been informed if you are a Person Discharging Managerial Responsibilities. In the case of any uncertainty, please contact the Compliance Officer.

"Prohibited Period" means any period other than a Closed Period which the Compliance Officer has determined to be a sensitive period. In the event of a public announcement of Inside Information by the Company, the Prohibited Period shall also cover the period starting as from the public announcement of Inside Information and ending at the close of the day during which such announcement was made, unless the Compliance Officer determined otherwise.

"Staff Member" means:

- a) any person employed by, or in any other type of employ of, Sequana Medical (including, for the avoidance of doubt, independent contractors), irrespective of the duration thereof; and
- b) any member of the board of directors, supervisory body, or executive management of Sequana Medical.

3. Inside Information and insider list

3.1. Inside Information

Inside Information means information:

- of a precise nature,
- which has not been made public,
- relating, directly or indirectly, to the Company or to one or more of the Company's Financial Instruments (such as the Company's shares), and
- which, if it were made public, would be likely to have a significant effect on the prices of those Financial Instruments or on the price of related derivative financial instruments.

Information is deemed to be "*of a precise nature*" if it indicates a set of circumstances which exists or which may reasonably be expected to come into existence, or an event which has occurred or which may reasonably be expected to occur, where it is specific enough to enable a conclusion to be drawn as to the possible effect of that set of circumstances or event on the prices of the Financial Instruments or the related derivative financial instruments.

Information which, if it were made public, "*would be likely to have a significant effect on the prices of financial instruments or derivative financial instruments*" means information a reasonable investor would be likely to use as part of the basis of his or her investment decisions.

Also an intermediate step in a protracted process is deemed to be Inside Information if, by itself, it satisfies the criteria of Inside Information as set out above.

3.2. Insider list

The Compliance Officer shall draw up a list of all Staff Members who have access to Inside Information and of any other persons otherwise performing tasks through which they have access to Inside Information. The Compliance Officer shall promptly update the insider list in case there is a change in the reason for including a person already on the insider list, or in case a person is to be added to, or deleted from, the insider list.

All Staff Members and any other persons otherwise performing tasks through which they have access to Inside Information shall fully cooperate with the Compliance Officer with respect to the setting up and updating of the insider list. In particular, any person on the insider list shall promptly inform the Compliance Officer of any change in the information included in the insider list.

The Compliance Officer shall take all reasonable steps to ensure that any person on the insider list acknowledges in writing the legal and regulatory duties entailed and is aware of the sanctions applicable to insider dealing and the unlawful disclosure of Inside Information.

The Company shall provide the insider list to the FSMA as soon as possible upon its request.

4. Prohibition of insider dealing or unlawful disclosure of Inside Information

The Market Abuse Regulation imposes a number of specific prohibitions on any person who possesses Inside Information as a result of (a) being a member of the board of directors or the executive management of the Company, (b) having a holding in the capital of the Company, (c) having access to the information through the exercise of an employment, profession or duties, or (d) being involved in criminal activities. These prohibitions also apply to any person who possesses Inside Information under any other circumstances where that person knows or ought to know that it is Inside Information.

The prohibitions can be summarised as follows:

a) A person shall not engage or attempt to engage in insider dealing

Insider dealing arises where a person possesses Inside Information and uses that information by acquiring or disposing of, for its own account or for the account of a third party, directly or indirectly, Financial Instruments to which that information relates. The use of Inside Information by cancelling or amending an order concerning a Financial Instrument to which the information relates where the order was placed before the person concerned possessed the Inside Information, shall also be considered to be insider dealing.

Each person must also avoid placing himself or herself under suspicion of abusing Inside Information that he or she may be thought to have (e.g. by, depending on the circumstances, executing a transaction of a short-term nature).

Where the person is a legal person, the prohibition of insider dealing shall also apply to the natural persons who participate in the decision to carry out the acquisition, disposal, cancellation or amendment of an order for the account of the legal person concerned.

b) A person shall not recommend that another person engages in insider dealing or induce another person to engage in insider dealing

This means that it is prohibited for a person who possesses Inside Information to recommend to another person or induce another person, on the basis of that information, to acquire or dispose of Financial Instruments to which the Inside Information relates, or to cancel or amend an order concerning a Financial Instrument to which the Inside Information relates.

The use of recommendations or inducements amounts to insider dealing where the person using the recommendation or inducement knows or ought to know that it is based upon Inside Information.

c) A person shall not unlawfully disclose Inside Information

Unlawful disclosure of Inside Information arises where a person possesses Inside Information and discloses that information to any other person. As an exception to the foregoing, a disclosure of Inside Information is permitted when made on a need-to-

know basis in the normal exercise of an employment, a profession or duties, but only if the person receiving the information (i) owes a duty of confidentiality, regardless of whether such duty is based on a law, on regulations or on a contract, and (ii) has acknowledged and confirmed to comply with its obligations under applicable market abuse legislation with respect to such disclosed Inside Information.

The onward disclosure of recommendations or inducements referred to in prohibition b) above amounts to unlawful disclosure of Inside Information where the person disclosing the recommendation or inducement knows or ought to know that it was based on Inside Information.

The above prohibitions apply regardless of whether the person concerned makes any gain through the prohibited operation.

5. Prohibition of transactions during Closed Periods and Prohibited Periods

Staff Members, PDMRs and persons closely associated with PDMRs may not conduct any transactions on their own account or for the account of a third party, directly or indirectly, relating to the shares or debt instruments of the Company or to derivatives or other Financial Instruments linked to them during a Closed Period or a Prohibited Period, except if the board of directors of the Company has allowed, upon a reasoned written request by the applicant, any such transaction either:

- a) on a case-by-case basis due to the existence of exceptional circumstances, such as severe financial difficulty, which require the immediate sale of shares; or
- b) due to characteristics of the trading involved for transactions made under, or related to, an employee share or saving scheme, qualification or entitlement of shares, or transactions where the beneficial interest in the relevant security does not change.

The Compliance Officer will give notice of the Closed Periods and Prohibited Periods.

Staff Members, PDMRs and persons closely associated with PDMRs must advise the persons professionally arranging or executing transactions on their behalf and any other persons executing transactions on their behalf (in each case including where discretion is exercised) of the Closed Periods and Prohibited Periods and must instruct them not to deal during such periods. This requirement does not apply with respect to transactions by managers of a collective investment undertaking who operate with full discretion.

For the avoidance of doubt, the reporting requirements set out in Sections 6 and 7 also apply in case of any permitted transactions during Closed Periods and Prohibited Periods.

6. General notification requirements

Outside Closed Periods and Prohibited Periods, Staff Members, PDMRs and persons closely associated with PDMRs may not deal in shares or debt instruments of the Company or in derivatives or other Financial Instruments linked thereto, without notifying the Compliance Officer at least two (2) business days in advance of the proposed transaction by submitting a completed and signed Dealing Notification Form (a copy of which is attached hereto as Annex A), in which such person shall also confirm that he or she is not in the possession of any Inside Information.

Upon receipt of the notification, the Compliance Officer can formulate a negative advice on the intended transaction. The Staff Member, PDMR or Person Closely Associated With a PDMR should treat such advice as an explicit disapproval by the Company of the intended

transaction. However, should the Compliance Officer not formulate a negative advice (i.e. he or she does not give any advice or he or she gives clearance), this can never dismiss the Staff Member, PDMR or Person Closely Associated With a PDMR of his or her responsibility to comply with all applicable laws and the provisions of this Dealing Code.

After the dealing has been executed, the Staff Member, PDMR or Person Closely Associated With a PDMR shall inform the Compliance Officer thereof by e-mail (including any supporting documents), specifying the type(s) of Financial Instrument(s) involved, the nature of the dealing (purchase, sale, acceptance, etc.), the effective date and place of the dealing, the quantity of traded instruments, their unit price and the total dealing price. This notification must be made at the latest on the business day after the date of the transaction.

If the person wishing to deal is the Compliance Officer or a Person Closely Associated With the Compliance Officer, the notification and subsequent reporting must be made to the chief executive officer of the Company.

Transactions undertaken by persons professionally arranging or executing transactions or by another person on behalf of a Staff Member, a PDMR or a Person Closely Associated With a PDMR, including where discretion is exercised, are also subject to the prior and subsequent notification requirements set out in this Section 6. Staff Members, PDMRs and persons closely associated with a PDMR must therefore advise the persons acting on their behalf or for their account of the requirement to inform them of any transactions to be executed on their behalf or for their account in view of the notification requirements set out in this Dealing Code. By way of exception, transactions executed by managers of a collective investment undertaking who operate with full discretion do not need to be notified.

7. Notification requirements for PDMRs and persons closely associated with them

7.1. List of PDMRs and persons closely associated with them and notification of their obligations

The Compliance Officer shall draw up a list of all PDMRs and all persons closely associated with them, and shall regularly update such list. All PDMRs and persons closely associated with them shall fully cooperate with the Compliance Officer with respect to the setting up and updating of such list. In particular, any person on the list shall promptly inform the Compliance Officer of any change in the information included in the list.

The Compliance Officer shall notify the PDMRs of their obligations under this Dealing Code and the Market Abuse Regulation in writing by providing them with a copy of this Dealing Code and obtaining a signed copy of the Dealing Code Consent Form attached hereto as Annex B.

PDMRs shall notify the persons closely associated with them of their obligations under this Dealing Code and the Market Abuse Regulation in writing, shall keep a copy of such notifications, and shall use their best efforts to monitor compliance by such persons with their obligations under this Dealing Code and the Market Abuse Regulation. For purposes of making the notifications to persons closely associated with them, PDMRs can make use of the CAP Notification Form attached hereto as Annex C.

7.2. Notification of transactions to the Company and the FSMA

PDMRs and persons closely associated with them shall notify the Company and the FSMA of every transaction conducted on their own account relating to the shares or debt instruments of the Company or to derivatives or other Financial Instruments linked thereto. The notification

requirement applies to any subsequent transaction once a total amount of EUR 5,000 has been reached within a calendar year (calculated by adding without netting all relevant transactions).

Without prejudice to Section 6 above, such notifications must be made promptly and no later than three (3) business days after the date of the transaction. The notification must be made through the "eMT" application for online notifications, which can be accessed via:

- Dutch: <https://portal-fimis.fsma.be/nl/Account/HomePublic>;
- French: <https://portal-fimis.fsma.be/fr/Account/HomePublic>;
- English: <https://portal-fimis.fsma.be/en/Account/HomePublic>.

Transactions that must be notified include (but are not limited to) the following:

- a) acquisition, disposal, short sale, subscription or exchange;
- b) acceptance or exercise of a stock option, including of a stock option granted to managers or employees as part of their remuneration package, and the disposal of shares stemming from the exercise of a stock option;
- c) acquisition, disposal or exercise of rights, including put and call options, and warrants;
- d) subscription to a capital increase or debt instrument issuance;
- e) gifts and donations made or received, and inheritance received;
- f) pledging or lending of Financial Instruments.

In addition, transactions undertaken by persons professionally arranging or executing transactions or by another person on behalf of a PDMR or a Person Closely Associated With such a person must also be notified, including where discretion is exercised. PDMRs and persons closely associated with them must therefore advise the persons acting on their behalf or for their account of the requirement to inform them of any transactions to be executed on their behalf or for their account in view of the notification requirements set out in this Dealing Code. By way of exception, transactions executed by managers of a collective investment undertaking who operate with full discretion do not need to be notified.

The FSMA shall publish the notified transactions on its website.

8. Employee incentive plans

The provisions of this Dealing Code apply to transactions in the framework of employee incentive plans, subject to the terms and conditions set out in this Dealing Code and the applicable market abuse legislation. By way of example, reference can be made to items 7.2. b) and 7.2.c) of this Dealing Code.

9. Sanctions

Failure to comply with the applicable rules on market abuse and the provisions of this Dealing Code may lead to various sanctions:

- *administrative and criminal sanctions*: the FSMA may adopt a wide range of administrative measures and impose administrative fines and, in certain cases, the competent courts may impose imprisonment and/or criminal fines (subject to the

provisions of the Belgian Act of 2 August 2002 on the supervision of the financial sector and the financial services);

- *civil sanctions*: a breach of the provisions of this Dealing Code or applicable market abuse rules may cause prejudice to the Company, for which it reserves the right to apply for compensation and damages before the competent courts;
- *disciplinary sanctions*: the Company may take disciplinary measures (including, if appropriate, termination for cause of the employment, service or other contract or mandate).

10. Privacy

All information that is communicated to the Compliance Officer shall be treated in accordance with Regulation 2016/679 of the European parliament and of the council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (as amended from time to time) . The Company shall process personal data to set up an insider list and a list of PDMRs and persons closely associated with them in order to comply with the Market Abuse Regulation. The insider list set up by the Company may have to be disclosed to the FSMA upon its request. All persons on a list kept by the Company shall have access to their personal information and shall have the right to correct any data relating to them. The access right and correction right can be exercised by sending an e-mail to the Compliance Officer.

11. Compliance Officer

The Compliance Officer shall implement and monitor compliance with this Dealing Code.

Each Staff Member and PDMR acknowledges that the Compliance Officer is authorized to investigate all relevant transactions (to be) executed by him or her, or on his or her account or behalf. Each Staff Member and PDMR must provide the Compliance Officer with all information the compliance office will request in the context of this Dealing Code.

Please contact the Compliance Officer at complianceofficer@sequanamedical.com in case of any questions in relation to this Dealing Code or in case you have violated or know of any violations of this Dealing Code by any Staff Member or PDMR. In case the violation involves the Compliance Officer, please raise the matter with the chief executive officer of the Company.

ANNEXES:

- Annex A: Dealing Notification Form.
- Annex B: Dealing Code Consent Form.
- Annex C: CAP Notification Form.

Annex A: Dealing Notification Form

I, the undersigned, hereby notify Sequana Medical NV (the "**Company**") that:

- I act:

☐ for myself

☐ for (*describe other person or legal entity*): _____

(Please tick applicable box)

- I intend to:

☐ purchase

☐ accept

☐ sell

☐ exercise

☐ exercise and immediately sell

☐ (*describe other transaction*): _____

_____ (*number*) of

☐ share(s)

☐ subscription right(s)

☐ warrant(s)

☐ (*describe other Financial Instrument*): _____

of the Company.

(Please tick applicable box)

- I am not in the possession of any Inside Information as defined in the Dealing Code of the Company and/or the relevant legislation.

Signature: _____

Name: _____

Title: _____

Date: _____

Annex B: Dealing Code Consent Form

To: complianceofficer@sequanamedical.com

The terms used in this Dealing Code Consent Form have the meanings given to such terms in the Dealing Code of Sequana Medical NV (the "**Company**").

I, the undersigned, confirm that:

- I have received a copy of the Dealing Code;
- I have read and understood all provisions of the Dealing Code and undertake to comply with all provisions of the Dealing Code at all times;
- I am aware of the fact that, in addition to the Dealing Code, I am subject to the applicable legislation concerning market abuse (including the Market Abuse Regulation, as defined in the Dealing Code) which sets out, among others, the administrative and criminal sanctions in case of breach of such legislation;
- I am aware of the legal and regulatory duties applicable to persons who have access to Inside Information and of the sanctions applicable to insider dealing, recommending or inducing another person to engage in insider dealing and the unlawful disclosure of Inside Information;
- I consent to the disclosure of any of my personal information to the FSMA upon its request;
- I am aware of the fact that I am a PDMR within the meaning of the Dealing Code and the Market Abuse Regulation;
- I hereby grant a power of attorney to the Compliance Officer and any member of the legal department of the Company, acting individually, to make filings on my behalf to the "eMT" application for online notifications and to do all that is necessary in this respect;
- I shall notify a list with the identity of all persons closely associated with me within the meaning of the Dealing Code and the Market Abuse Regulation as soon as possible to the Compliance Officer and I undertake to inform the Compliance Officer promptly in case of any changes to such list;
- I have notified, or shall notify as soon as possible, the persons closely associated with me in writing of their obligations under the Dealing Code and the Market Abuse Regulation. I shall retain a copy of such notifications and shall use my best efforts to monitor compliance by the persons closely associated with me with respect to their obligations under the Dealing Code and the Market Abuse Regulation;
- I have notified, or shall notify as soon as possible, any investment managers acting on my behalf or for my account of the obligations under the Dealing Code.

Signature: _____

Name: _____

Title: _____

Date: _____

Annex C: CAP Notification Form

To: **[Person Closely Associated With PDMR]**

I, **[name of PDMR]** (the "**Notifying PDMR**"),

in my capacity as "person discharging managerial responsibility" within Sequana Medical NV (the "**Company**") or any of its subsidiaries for purposes of Regulation EU No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (the "**Market Abuse Regulation**"), as well as for purposes of the Dealing Code of the Company (the "**Dealing Code**"),

hereby inform you, **[name of Person Closely Associated With PDMR]** (the "**Recipient**"), of the following:

- As a result of your relationship or affiliation to me, you are a "person closely associated" for purposes of the Market Abuse Regulation and the Dealing Code;
- As a "person closely associated", you are subject to the relevant provisions of the Market Abuse Regulation and the Dealing Code (as attached hereto in schedule);
- In particular, you are subject to the requirements provided for by Article 19 of the Market Abuse Regulation (as also further detailed in the Dealing Code) with respect to your dealings relating to shares or debt instruments of the Company or to derivatives or other financial instruments linked thereto;
- The Company shall draw up a list of all "persons discharging managerial responsibility" and all "persons closely associated" with them (i.e., including you); and
- You are subject to the applicable legislation on market abuse (including the Market Abuse Regulation) which sets out, among others, the administrative and criminal sanctions in case of breach of such legislation.

Signed by the Notifying PDMR

Signed for receipt by the Recipient

Signature: _____

Signature: _____

Name: _____

Name: _____

Title: _____

Title: _____

Date: _____

Date: _____

Schedule: Copy of the Dealing Code.